There are currently 957 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama-Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
NCT05312879
Recruiting
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Gender:
ALL
Ages:
Between 10 years and 65 years
Trial Updated:
08/21/2025
Locations: EmVenio Research - Mobile Unit - Birmingham, Birmingham, Alabama +3 locations
Conditions: Proteinuric Kidney Disease
Register for Updates
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
NCT04530565
Recruiting
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/20/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Register for Updates
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670
Recruiting
The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers. This study is open to adults with ulcerative PG with at least 1 ulcer that measures between 5 cm\^2 to 80 cm\^2 in size. This study has 2 parts. In Part 1, participants are put into groups randomly, which means by chance. 1 group gets spesolimab and the other group gets placebo. Placebo injections look... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Pyoderma Gangrenosum
Register for Updates
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
NCT06098079
Recruiting
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: Accel Research Sites Network, Birmingham, Alabama
Conditions: Obesity
Register for Updates
Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation
NCT06364215
Recruiting
The purpose of this study is to compare the efficacy and safety between pulmonary vein isolation (PVI) alone versus PVI with left atrial (LA) posterior wall isolation (PWI) using pulsed-field ablation (PFA) in the treatment of patients with paroxysmal atrial fibrillation (PAF).
Gender:
ALL
Ages:
Between 21 years and 90 years
Trial Updated:
08/20/2025
Locations: Grandview Medical Center, Birmingham, Alabama
Conditions: Atrial Fibrillation Paroxysmal
Register for Updates
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/20/2025
Locations: Accel Research, Birmingham, Alabama
Conditions: Focal Epilepsy
Register for Updates
Study of JK07 in Patients With Chronic Heart Failure
NCT06369298
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%. Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) \> 40% and ≤ 65%.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/20/2025
Locations: Site 130, Birmingham, Alabama +1 locations
Conditions: Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Register for Updates
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
NCT05605899
Recruiting
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: University of Alabama Hospital, Birmingham, Alabama
Conditions: High-risk Large B-cell Lymphoma (LBCL)
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/20/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479
Recruiting
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: Local Institution - 0071, Birmingham, Alabama
Conditions: Relapsed or Refractory Multiple Myeloma (RRMM)
Register for Updates
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029
Recruiting
The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: Local Institution - 0001, Birmingham, Alabama
Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
Register for Updates
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541
Recruiting
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-00... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: Total Dermatology, Birmingham, Alabama
Conditions: Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
Register for Updates